Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 518 participants.
Also called NCT02369549
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 518 participants
- Sponsor
- Registry
-
NCT02369549
-
- Other papers using this trial's data
- The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT02369549. Randomized; quadruple masking; primary purpose prevention. Start 2015-09 (actual); primary completion 2019-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
- Acronym
- MPAC-CKD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Micro-particle Curcumin
- Intervention (Drug)
- Placebo
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Collaborator
- The Kidney Foundation of Canada
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct02369549- Content hash
2fd570050375e22c0bb309a853d2f8e757445d2a1ba9eceb01201d0831be0a33